Cure8 news brief
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
If you or a clinician are weighing benefits and risks of JAK inhibitor therapy, these pooled trial data highlight overall tolerability and a noted increase in shingles risk.
Adults with moderate-to-severe UC or Crohn’s disease considering or taking upadacitinib, clinicians who manage IBD, and researchers following long-term safety of JAK inhibitors.
Serious events such as adjudicated major adverse cardiac events (MACE), malignancy and venous thromboembolism were rare in the pooled IBD trial data. Common adverse events included acne, nasopharyngitis, neutropenia/lymphopenia, transient liver enzyme elevations and COVID-19 during the pandemic period.
Herpes zoster cases were generally described as mild and localized and occurred most often in unvaccinated patients. What this does not say: The article summarizes a post hoc pooled safety analysis and notes limitations, including differing exposure times between placebo and upadacitinib groups and a trial population with few comorbidities.
It does not provide guidance to change individual treatment; vaccine history and individual risks should be discussed with a clinician. Where the data came from: Healio’s report summarizes an integrated analysis published in Clinical Gastroenterology and Hepatology by Panaccione and colleagues and commentary by Rubin and coauthors.
This is a pooled, post hoc clinical-trial safety analysis (not a randomized long-term head-to-head safety trial or real-world registry). Reported herpes zoster increases were more common at higher doses and among unvaccinated patients. The article notes limited comorbidity representation and shorter placebo exposure, so real-world studies may provide additional information.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
